Should we adjust erythropoiesis-stimulating agent dosage to postdialysis hemoglobin levels? A pilot study

BMC Nephrology

Table 4 Partial Cox regression models to predict CVE controlling by age and comorbidities

	HR	95% CI	P
*Model 1*
EPO dose (IU/week)	1.015	1.010-1.020	0.032
Ischemic heart disease	2.66	0.920-7.650	0.069
*Model 2*
EPO dose (IU/week)	1.0015	1.001-1.002	0.049
Heart failure	2.29	0.710-7.270	0.16
*Model 3*
EPO dose (IU/week)	1.00	0.999-1.001	0.058
Stroke	1.72	0.380-7.750	0.47
*Model 4*
EPO dose (IU/week)	1.00	0.999-1.001	0.06
Age (years)	1.005	0.967-1.045	0.79
*Model 5*
EPO dose (IU/week)	1.000	0.999-1.001	0.065
Arrythmia	1.17	0.330-4.170	0.80
*Model 6*
EPO dose (IU/week)	1.000	0.999-1.001	0.094
Diabetes	0.468	0.163-1.345	0.159
*Model 7*
EPO dose (IU/week)	1.000	0.999-1.001	0.105
Peripheral vascular disease	1.702	0.539-5.372	0.36

ISSN: 1471-2369